Threshold Pharmaceuticals Inc

Type: Company
Name: Threshold Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.thresholdpharm.com/
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

TH-302 demonstrates encouraging activity in soft tissue sarcoma

The investigational hypoxia-targeted drug TH-302 was associated with PFS, OS and tumor response rates that compared favorably with other first-line agents for soft tissue sarcoma, according to results of a phase 2 study.The analysis included 91 patients ... [Published Orthopedics Today - Sep 23 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Threshold down on Phase III data delay

Threshold Pharmaceuticals Inc. (NASDAQ:THLD) fell $0.50 (11%) to $3.97 on Monday after saying it expects delayed data from its Phase III trial of TH-302 to treat unresectable or metastatic soft tissue sarcoma (STS).The delay is based on the results o ... [Published BioPortfolio - Sep 23 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Healthcare Review: Genetic Technologies, Progenics Pharmaceuticals, Repros Therapeutics, Tekmira Pharmaceuticals, Threshold Pharmaceuticals

U.S. stocks fell on Monday, with the Dow Jones Industrial Average stepping back from an all-time high, as uncertainty about China's growth injected caution into global markets. Stocks' cautious tone began overnight, after China's financial minister said ... [Published BioMedReports - Sep 22 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Uptrend Call Working As Threshold Pharmaceuticals Stock Rises 19.5% (THLD)

Written on Thu, 09/11/2014 - 6:22pmBy Amy SchwartzSmarTrend identified an Uptrend for Threshold Pharmaceuticals ( NASDAQ:THLD ) on June 9th, 2014 at $4.21. In approximately 3 months, Threshold Pharmaceuticals has returned 19.48% as of today's recent ... [Published Comtex SmarTrend - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Uptrend Call Working As Threshold Pharmaceuticals Stock Rises 19.5% (THLD)

SmarTrend identified an Uptrend for Threshold Pharmaceuticals (NASDAQ:THLD) on June 9th, 2014 at $4.21. In approximately 3 months, Threshold Pharmaceuticals has returned 19.48% as of today's recent price of $5. ... [Published Individual.com - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Events for the Week of Sept. 8-12

Rodman & Renshaw 2014 Annual Global Investment Conference – Sep. 08 to Sep. 10 - New York City Companies to participate: PCM, Inc. (NASDAQ: PCMI[1]) Oncothyreon Inc. (NASDAQ: ONTY[2]) PositiveID Corporation (OTC: PSID[3]) Cytomedix (OTC: CMXI[4]) China ... [Published DailyMe.Com - Sep 10 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Apple Unveils Watch, Larger iPhones; Francesca's Shares Drop After Downbeat Results

At the end of trading on Tuesday, the Dow traded down 0.57 percent to 17,013.87 while the NASDAQ declined 0.87 percent to 4,552.29. ...Related Stocks:ANNIE'S, Inc. Apple Inc. BURLINGTON STORES, Inc. COMPANHIA PARAN. DE ENERG CPFL ENERGIA S.A. ENDOCYTE ... [Published MoneyShow.com - Sep 09 2014]
Entities: Apple Inc, iPhone, Stocks
First reported Sep 08 2014 - Updated Sep 09 2014 - 2 reports

Threshold adds to yesterday's pop

News EditorShares of micro cap Threshold Pharmaceuticals (THLD +10.2%) gap up on a 7x surge in volume. Prices are up 30% in two days.Cantor Fitzgerald initiates coverage with a $14 PT. H.C. Wainwright jumps in as well with a $12 PT.Individual investors ... [Published Seeking Alpha - Sep 09 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Top Analysts Action: IPCI, IL, CLH, VRTS, FNSR

Intellipharmaceutics Intl (IPCI) Maxim Group raises rating to buy from hold, price target to $7.00 from $3.00IntraLinks Holdings (IL) Stifel raises rating to buy from hold, price target $15.00Clean Harbors (CLH) BB&T Capital Mkts lowers to hold from ... [Published BayStreet.ca - Sep 05 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Notable Upgrades: Akamai Technologies (AKAM), Vertex Pharmaceuticals (VRTX), Avago Technologies (AVGO) , Threshold Pharmaceuticals (THLD), Intellipharmaceutics (IPCI)

UBS AG is out with a report this morning initiating coverage of Akamai Technologies, Inc. (AKAM) with a ‘Buy’ rating and $70 price target, implying 16% expected return. The Swiss global financial services firm said it sees the cloud services provider ... [Published Wall Street Pit - Sep 05 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 3 reports

Threshold Pharmaceuticals Coverage Initiated at HC Wainwright (THLD)

Stock analysts at HC Wainwright initiated coverage on shares of Threshold Pharmaceuticals (NASDAQ:THLD)Separately, analysts at Brean Capital initiated coverage on shares of Threshold Pharmaceuticals in a research note on Tuesday, July 8th. They set a ... [Published American Banking News - Stock Ratings - Sep 05 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 2 reports

Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw 16th Annual Global Investment Conference

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/02/14 -- Threshold Pharmaceuticals, Inc. ( NASDAQ: THLD ) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Rodman & Renshaw 16th Annual ... [Published Market Pulse Navigator - Sep 02 2014]

Quotes

...President and CEO Dr. Mark J Murray says, "Our TKM-Ebola drug supplies are limited, but we will continue to help where we can as we continue to focus on the other important objectives we have to advance therapies to meet the unmet needs of patients."

More Content

All (42) | News (29) | Reports (0) | Blogs (13) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Pyruvate Induces Transient Tumor Hypoxia by Enh... [Published Plosone.org - Sep 25 2014]
TH-302 demonstrates encouraging activity in sof... [Published Orthopedics Today - Sep 23 2014]
Threshold down on Phase III data delay [Published BioPortfolio - Sep 23 2014]
Threshold drug moves forward on cancer trial bu... [Published San Francisco Business Times - Sep 22 2014]
Healthcare Review: Genetic Technologies, Progen... [Published BioMedReports - Sep 22 2014]
Threshold Pharma Says Phase 3 Trial of TH-302 i... [Published Austin American Statesman - Sep 22 2014]
Threshold Pharma Says Phase 3 Trial of TH-302 i... [Published Benzinga.com - Sep 22 2014]
Threshold Pharmaceuticals Announces Its Phase 3... [Published Marketwire - Breaking News Releases - Sep 22 2014]
Uptrend Call Working As Threshold Pharmaceutica... [Published Comtex SmarTrend - Sep 12 2014]
Uptrend Call Working As Threshold Pharmaceutica... [Published Individual.com - Sep 11 2014]
Events for the Week of Sept. 8-12 [Published DailyMe.Com - Sep 10 2014]
Apple Unveils Watch, Larger iPhones; Francesca'... [Published MoneyShow.com - Sep 09 2014]
Threshold adds to yesterday's pop [Published Seeking Alpha - Sep 09 2014]
Research Analysts’ New Coverage for September, ... [Published American Banking News - Sep 08 2014]
Threshold Pharmaceuticals Receives New Coverage... [Published American Banking News - Forex - Sep 08 2014]
Top Analysts Action: IPCI, IL, CLH, VRTS, FNSR [Published BayStreet.ca - Sep 05 2014]
Threshold Pharmaceuticals Coverage Initiated at... [Published American Banking News - Stock Ratings - Sep 05 2014]
Notable Upgrades: Akamai Technologies (AKAM), V... [Published Wall Street Pit - Sep 05 2014]
Threshold Pharmaceuticals, Inc. Shares Jump Ami... [Published Atlanta Journal And Constitution - Sep 05 2014]
Threshold Pharmaceuticals, Inc. Shares Jump Ami... [Published Benzinga.com - Sep 05 2014]
Investment Analysts’ New Coverage for September... [Published American Banking News - Forex - Sep 05 2014]
Threshold Pharmaceuticals Announces Presentatio... [Published Market Pulse Navigator - Sep 02 2014]
Threshold Pharmaceuticals Announces Presentatio... [Published Marketwire - Breaking News Releases - Sep 02 2014]
BioNews [8.29.14] [Published eClinical Trends - Aug 29 2014]
Clinical Trial Results To Watch [Published Seeking Alpha - Aug 25 2014]
Biotech Stock Mailbag: Threshold, Galena, CytRx [Published TheStreet.com - Aug 22 2014]
Biotech Stock Mailbag: Threshold, Galena, CytRx [Published The Street Latest - Aug 22 2014]
5 Stocks Ready for Breakouts [Published The Street Latest - Aug 11 2014]
4 Biotech Stocks Under $10 to Trade for Breakouts [Published The Street Latest - Aug 01 2014]
Threshold Pharmaceuticals Reports Second Quarte... [Published Marketwire - Breaking News Releases - Aug 01 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Threshold Pharmaceuticals Announces Its Phase 3... [Published Marketwire - Breaking News Releases - Sep 22 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 22, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the Independent Data Monitoring Committee (IDMC) has completed the planned interim efficacy and safety analyses of unblinded ...
Threshold Pharmaceuticals Announces Presentatio... [Published Marketwire - Breaking News Releases - Sep 02 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 2, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Rodman & Renshaw 16th Annual ...
BioNews [8.29.14] [Published eClinical Trends - Aug 29 2014]
Top News HeadlineCompanyType Band of West Coast biotech insiders pushes oral anticoagulant to PhIII Armetheon, Inc.Study Gilead Sciences, Inc., "The New Genentech," Remaps Massive Foster City Campus Gilead Sciences, Inc.Expanding Offic ...
Threshold Pharmaceuticals Reports Second Quarte... [Published Marketwire - Breaking News Releases - Aug 01 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Aug 1, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the second quarter 2014. Revenue for the second quarter ended June 30, 2014 was $3.7 million. The operating loss ...
Threshold Announces Initiation of Dosing With T... [Published Marketwire - Breaking News Releases - Jul 09 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 9, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.